The estimated Net Worth of Andrea Loewen is at least $7.81 Milión dollars as of 14 September 2023. Ms. Loewen owns over 3,175 units of Reata Pharmaceuticals Inc stock worth over $4,897,782 and over the last 9 years she sold RETA stock worth over $2,910,934. In addition, she makes $0 as Vice President - Global Regulatory Affairs at Reata Pharmaceuticals Inc.
Andrea has made over 4 trades of the Reata Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 3,175 units of RETA stock worth $546,195 on 14 September 2023.
The largest trade she's ever made was selling 19,036 units of Reata Pharmaceuticals Inc stock on 7 March 2023 worth over $1,588,173. On average, Andrea trades about 4,457 units every 28 days since 2016. As of 14 September 2023 she still owns at least 28,416 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Ms. Loewen stock trades at the bottom of the page.
Andrea Loewen serves as Vice President - Global Regulatory Affairs of the Company. Her career in the biopharmaceutical industry spans more than 30 years at Shire, Biogen, Baxter Healthcare, and a number of smaller biopharmaceutical companies. She has significant leadership experience developing and implementing innovative regulatory strategies, building out global regulatory organizations and capabilities, engaging and negotiating with health authorities, and preparing and filing development and registration dossiers, including New Drug Applications (NDAs), Biologics License Applications, and EU Marketing Authorisation Applications (MAAs).
Andrea's mailing address filed with the SEC is 5320 LEGACY DRIVE, , PLANO, TX, 75024.
Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy a Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include: